These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1951354)

  • 41. Renal disease in Colombia.
    Gómez RA
    Ren Fail; 2006; 28(8):643-7. PubMed ID: 17162422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiology of end stage renal disease and implications for public policy.
    Rubin RJ
    Public Health Rep; 1984; 99(5):492-8. PubMed ID: 6435162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The cost of dialysis and kidney transplantation in the economically developed countries].
    Denisov VK
    Klin Khir; 1998; (9-10):74-6. PubMed ID: 10050412
    [No Abstract]   [Full Text] [Related]  

  • 45. A simulation model to estimate the cost and effectiveness of alternative dialysis initiation strategies.
    Lee CP; Chertow GM; Zenios SA
    Med Decis Making; 2006; 26(5):535-49. PubMed ID: 16997929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Helping patients with end-stage renal disease.
    Kuchta K; VanBuskirk S; Houglum M
    Am J Nurs; 2007 May; 107(5):35-6. PubMed ID: 17443073
    [No Abstract]   [Full Text] [Related]  

  • 47. Unequal access to cadaveric kidney transplantation in California based on insurance status.
    Thamer M; Henderson SC; Ray NF; Rinehart CS; Greer JW; Danovitch GM
    Health Serv Res; 1999 Oct; 34(4):879-900. PubMed ID: 10536975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004.
    Cusumano A; Garcia GG; Di Gioia C; Hermida O; Lavorato C;
    Ethn Dis; 2006; 16(2 Suppl 2):S2-10-3. PubMed ID: 16774002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Why we need the option of more dialysis.
    Hodge MH
    Nephrol News Issues; 2006 Oct; 20(11):76, 78-9. PubMed ID: 17039973
    [No Abstract]   [Full Text] [Related]  

  • 51. Current status of chronic kidney disease care in southeast Asia.
    Jha V
    Semin Nephrol; 2009 Sep; 29(5):487-96. PubMed ID: 19751894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicare and erythropoietin.
    Steinbrook R
    N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
    [No Abstract]   [Full Text] [Related]  

  • 53. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States.
    Collins AJ; Kasiske B; Herzog C; Chavers B; Foley R; Gilbertson D; Grimm R; Liu J; Louis T; Manning W; Matas A; McBean M; Murray A; St Peter W; Xue J; Fan Q; Guo H; Li S; Li S; Roberts T; Snyder J; Solid C; Wang C; Weinhandl E; Arko C; Chen SC; Dalleska F; Daniels F; Dunning S; Ebben J; Frazier E; Johnson R; Sheets D; Forrest B; Berrini D; Constantini E; Everson S; Frederick P; Eggers P; Agodoa L;
    Am J Kidney Dis; 2005 Jan; 45(1 Suppl 1):A5-7, S1-280. PubMed ID: 15640975
    [No Abstract]   [Full Text] [Related]  

  • 54. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of treatment costs between dialysis and transplantation.
    Eggers P
    Semin Nephrol; 1992 May; 12(3):284-9. PubMed ID: 1615249
    [No Abstract]   [Full Text] [Related]  

  • 56. An interview with Rep. Charles A. Vanik (D-OH).
    Lesparre M; Vanik A
    Hospitals; 1976 Jul; 50(14):45-6, 49-50. PubMed ID: 780255
    [No Abstract]   [Full Text] [Related]  

  • 57. How will the mid-term elections impact ESRD?
    Blaser R
    Nephrol News Issues; 2011 Jan; 25(1):22, 24. PubMed ID: 21291052
    [No Abstract]   [Full Text] [Related]  

  • 58. Costs and financing of kidney transplantation in the United States.
    Mendez R; Aswad S; Dessouki A; Cicciarelli J; Mendez RG
    Transplant Proc; 1992 Oct; 24(5):2127-8. PubMed ID: 1413009
    [No Abstract]   [Full Text] [Related]  

  • 59. The cost-effectiveness of transplantation with expanded donor kidneys.
    Whiting JF; Zavala EY; Alexander JW; First MR
    Transplant Proc; 1999; 31(1-2):1320-1. PubMed ID: 10083588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Budget pressures affecting kidney patients and providers.
    Schrag WF
    Nephrol News Issues; 2011 Jan; 25(1):26. PubMed ID: 21291053
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.